Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2024 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
impact P1093 team[Corporate Author]
(1 results)?
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Lancet HIV. 2022 May;9(5):e332-e340. doi: 10.1016/S2352-3018(22)00044-3.
Lancet HIV. 2022.
PMID: 35489377
Free PMC article.
Clinical Trial.
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.
Chandasana H, Hayes S, Buchanan AM, Brothers C, Wiznia A, Bartlett M, Popson S, Townley E, George K, Vavro C, Ruel T, Acosta EP, Singh R; IMPAACT P1093 Team.
Chandasana H, et al.
AIDS. 2024 May 20. doi: 10.1097/QAD.0000000000003929. Online ahead of print.
AIDS. 2024.
PMID: 38768443
Item in Clipboard
Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.
Spector SA, Brummel SS, Chang A, Wiznia A, Ruel TD, Acosta EP; for IMPAACT P1093 Team.
Spector SA, et al.
J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):297-303. doi: 10.1097/QAI.0000000000003358.
J Acquir Immune Defic Syndr. 2024.
PMID: 38180896
Item in Clipboard
Cite
Cite